Which has stronger valuation & earnings, SLDB or GALT?

Galectin Therapeutics is trading at a lower price-to-earnings ratio than Solid Biosciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Solid Biosciences N/A N/A -$174.32M -$1.95 N/A Galectin Therapeutics N/A N/A -$30.84M -$0.41 N/A

Is SLDB or GALT more profitable?

Galectin Therapeutics' return on equity of 0.00% beat Solid Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Solid Biosciences N/A -73.42% -61.13% Galectin Therapeutics N/A N/A -164.69%

Does the media favor SLDB or GALT?

In the previous week, Solid Biosciences had 1 more articles in the media than Galectin Therapeutics. MarketBeat recorded 4 mentions for Solid Biosciences and 3 mentions for Galectin Therapeutics. Solid Biosciences' average media sentiment score of 0.72 beat Galectin Therapeutics' score of 0.27 indicating that Solid Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Solid Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Galectin Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable valuation & earnings, GALT or CLYM?

Climb Bio is trading at a lower price-to-earnings ratio than Galectin Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Galectin Therapeutics N/A N/A -$30.84M -$0.41 N/A Climb Bio N/A N/A -$59.85M -$0.78 N/A

Is GALT or CLYM more profitable?

Galectin Therapeutics' return on equity of 0.00% beat Climb Bio's return on equity. Company Net Margins Return on Equity Return on Assets Galectin Therapeutics N/A N/A -164.69% Climb Bio N/A -31.45% -30.39%

Do analysts recommend GALT or AVTE?

Galectin Therapeutics currently has a consensus target price of $11.00, suggesting a potential upside of 368.09%. Given Galectin Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Galectin Therapeutics is more favorable than Aerovate Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Galectin Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Aerovate Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has better valuation and earnings, GALT or AVTE?

Aerovate Therapeutics is trading at a lower price-to-earnings ratio than Galectin Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Galectin Therapeutics N/A N/A -$30.84M -$0.41 N/A Aerovate Therapeutics N/A N/A -$75.52M -$1.70 N/A

Is GALT or AVTE more profitable?

Galectin Therapeutics' return on equity of 0.00% beat Aerovate Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Galectin Therapeutics N/A N/A -164.69% Aerovate Therapeutics N/A -90.19% -77.47%

Does the media favor GALT or CTMX?

In the previous week, Galectin Therapeutics and Galectin Therapeutics both had 3 articles in the media. Galectin Therapeutics' average media sentiment score of 0.27 beat CytomX Therapeutics' score of 0.18 indicating that Galectin Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Galectin Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral CytomX Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media prefer TLRY or GALT?

In the previous week, Tilray Brands had 10 more articles in the media than Galectin Therapeutics. MarketBeat recorded 13 mentions for Tilray Brands and 3 mentions for Galectin Therapeutics. Tilray Brands' average media sentiment score of 0.29 beat Galectin Therapeutics' score of 0.27 indicating that Tilray Brands is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tilray Brands 3 Very Positive mention(s) 0 Positive mention(s) 7 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral Galectin Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Galectin Therapeutics (GALT) Competitors

$2.35 -0.07 (-2.89%)

As of 04:00 PM Eastern

Compare

GALT vs. SLDB, CLYM, AVTE, CTMX, and TLRY

Should you buy Galectin Therapeutics stock or one of its competitors? MarketBeat compares Galectin Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Galectin Therapeutics include Solid Biosciences (SLDB), Climb Bio (CLYM), Aerovate Therapeutics (AVTE), CytomX Therapeutics (CTMX), and Tilray Brands (TLRY). These companies are all part of the "pharmaceutical products" industry.

How does Galectin Therapeutics compare to Solid Biosciences?

Solid Biosciences (NASDAQ:SLDB) and Galectin Therapeutics (NASDAQ:GALT) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, risk, valuation, earnings, dividends and media sentiment.

Solid Biosciences presently has a consensus price target of $16.82, suggesting a potential upside of 145.52%. Galectin Therapeutics has a consensus price target of $11.00, suggesting a potential upside of 368.09%. Given Galectin Therapeutics' higher possible upside, analysts plainly believe Galectin Therapeutics is more favorable than Solid Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Solid Biosciences	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.92
Galectin Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Galectin Therapeutics' return on equity of 0.00% beat Solid Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Solid Biosciences	N/A	-73.42%	-61.13%
Galectin Therapeutics	N/A	N/A	-164.69%

In the previous week, Solid Biosciences had 1 more articles in the media than Galectin Therapeutics. MarketBeat recorded 4 mentions for Solid Biosciences and 3 mentions for Galectin Therapeutics. Solid Biosciences' average media sentiment score of 0.72 beat Galectin Therapeutics' score of 0.27 indicating that Solid Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Solid Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Galectin Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Galectin Therapeutics is trading at a lower price-to-earnings ratio than Solid Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Solid Biosciences	N/A	N/A	-$174.32M	-$1.95	N/A
Galectin Therapeutics	N/A	N/A	-$30.84M	-$0.41	N/A

81.5% of Solid Biosciences shares are held by institutional investors. Comparatively, 11.7% of Galectin Therapeutics shares are held by institutional investors. 2.7% of Solid Biosciences shares are held by insiders. Comparatively, 52.6% of Galectin Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Solid Biosciences has a beta of 2.43, suggesting that its share price is 143% more volatile than the broader market. Comparatively, Galectin Therapeutics has a beta of 0.47, suggesting that its share price is 53% less volatile than the broader market.

Summary

Solid Biosciences beats Galectin Therapeutics on 9 of the 14 factors compared between the two stocks.

How does Galectin Therapeutics compare to Climb Bio?

Galectin Therapeutics (NASDAQ:GALT) and Climb Bio (NASDAQ:CLYM) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, risk, valuation, analyst recommendations, media sentiment, dividends and earnings.

Climb Bio is trading at a lower price-to-earnings ratio than Galectin Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Galectin Therapeutics	N/A	N/A	-$30.84M	-$0.41	N/A
Climb Bio	N/A	N/A	-$59.85M	-$0.78	N/A

Galectin Therapeutics has a beta of 0.47, meaning that its stock price is 53% less volatile than the broader market. Comparatively, Climb Bio has a beta of 0.09, meaning that its stock price is 91% less volatile than the broader market.

11.7% of Galectin Therapeutics shares are held by institutional investors. Comparatively, 69.8% of Climb Bio shares are held by institutional investors. 52.6% of Galectin Therapeutics shares are held by insiders. Comparatively, 2.6% of Climb Bio shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Galectin Therapeutics had 2 more articles in the media than Climb Bio. MarketBeat recorded 3 mentions for Galectin Therapeutics and 1 mentions for Climb Bio. Climb Bio's average media sentiment score of 1.87 beat Galectin Therapeutics' score of 0.27 indicating that Climb Bio is being referred to more favorably in the news media.

Company	Overall Sentiment
Galectin Therapeutics	Neutral
Climb Bio	Very Positive

Galectin Therapeutics currently has a consensus target price of $11.00, suggesting a potential upside of 368.09%. Climb Bio has a consensus target price of $20.30, suggesting a potential upside of 94.44%. Given Galectin Therapeutics' higher possible upside, equities analysts plainly believe Galectin Therapeutics is more favorable than Climb Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Galectin Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Climb Bio	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	3 Strong Buy rating(s)	3.08

Galectin Therapeutics' return on equity of 0.00% beat Climb Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Galectin Therapeutics	N/A	N/A	-164.69%
Climb Bio	N/A	-31.45%	-30.39%

Summary

Galectin Therapeutics beats Climb Bio on 8 of the 14 factors compared between the two stocks.

How does Galectin Therapeutics compare to Aerovate Therapeutics?

Galectin Therapeutics (NASDAQ:GALT) and Aerovate Therapeutics (NASDAQ:AVTE) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, institutional ownership, analyst recommendations, media sentiment, earnings, dividends, valuation and profitability.

In the previous week, Galectin Therapeutics had 3 more articles in the media than Aerovate Therapeutics. MarketBeat recorded 3 mentions for Galectin Therapeutics and 0 mentions for Aerovate Therapeutics. Aerovate Therapeutics' average media sentiment score of 0.67 beat Galectin Therapeutics' score of 0.27 indicating that Aerovate Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Galectin Therapeutics	Neutral
Aerovate Therapeutics	Positive

Galectin Therapeutics' return on equity of 0.00% beat Aerovate Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Galectin Therapeutics	N/A	N/A	-164.69%
Aerovate Therapeutics	N/A	-90.19%	-77.47%

Aerovate Therapeutics is trading at a lower price-to-earnings ratio than Galectin Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Galectin Therapeutics	N/A	N/A	-$30.84M	-$0.41	N/A
Aerovate Therapeutics	N/A	N/A	-$75.52M	-$1.70	N/A

Galectin Therapeutics currently has a consensus target price of $11.00, suggesting a potential upside of 368.09%. Given Galectin Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Galectin Therapeutics is more favorable than Aerovate Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Galectin Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Aerovate Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

11.7% of Galectin Therapeutics shares are held by institutional investors. 52.6% of Galectin Therapeutics shares are held by insiders. Comparatively, 24.9% of Aerovate Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Galectin Therapeutics has a beta of 0.47, meaning that its share price is 53% less volatile than the broader market. Comparatively, Aerovate Therapeutics has a beta of 0.95, meaning that its share price is 5% less volatile than the broader market.

Summary

Galectin Therapeutics beats Aerovate Therapeutics on 10 of the 13 factors compared between the two stocks.

How does Galectin Therapeutics compare to CytomX Therapeutics?

Galectin Therapeutics (NASDAQ:GALT) and CytomX Therapeutics (NASDAQ:CTMX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, risk, institutional ownership, profitability, earnings, media sentiment, dividends and valuation.

In the previous week, Galectin Therapeutics and Galectin Therapeutics both had 3 articles in the media. Galectin Therapeutics' average media sentiment score of 0.27 beat CytomX Therapeutics' score of 0.18 indicating that Galectin Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Galectin Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
CytomX Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Galectin Therapeutics has a net margin of 0.00% compared to CytomX Therapeutics' net margin of -166.40%. Galectin Therapeutics' return on equity of 0.00% beat CytomX Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Galectin Therapeutics	N/A	N/A	-164.69%
CytomX Therapeutics	-166.40%	-36.61%	-28.02%

Galectin Therapeutics presently has a consensus target price of $11.00, suggesting a potential upside of 368.09%. CytomX Therapeutics has a consensus target price of $12.10, suggesting a potential upside of 275.78%. Given Galectin Therapeutics' higher probable upside, equities research analysts plainly believe Galectin Therapeutics is more favorable than CytomX Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Galectin Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
CytomX Therapeutics	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.91

Galectin Therapeutics has a beta of 0.47, suggesting that its stock price is 53% less volatile than the broader market. Comparatively, CytomX Therapeutics has a beta of 2.08, suggesting that its stock price is 108% more volatile than the broader market.

11.7% of Galectin Therapeutics shares are owned by institutional investors. Comparatively, 67.8% of CytomX Therapeutics shares are owned by institutional investors. 52.6% of Galectin Therapeutics shares are owned by insiders. Comparatively, 6.6% of CytomX Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

CytomX Therapeutics has higher revenue and earnings than Galectin Therapeutics. CytomX Therapeutics is trading at a lower price-to-earnings ratio than Galectin Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Galectin Therapeutics	N/A	N/A	-$30.84M	-$0.41	N/A
CytomX Therapeutics	$76.20M	7.19	-$17.37M	-$0.41	N/A

Summary

CytomX Therapeutics beats Galectin Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Galectin Therapeutics compare to Tilray Brands?

Tilray Brands (NASDAQ:TLRY) and Galectin Therapeutics (NASDAQ:GALT) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, earnings, media sentiment, profitability, analyst recommendations, institutional ownership, valuation and dividends.

9.4% of Tilray Brands shares are owned by institutional investors. Comparatively, 11.7% of Galectin Therapeutics shares are owned by institutional investors. 0.8% of Tilray Brands shares are owned by insiders. Comparatively, 52.6% of Galectin Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Galectin Therapeutics has lower revenue, but higher earnings than Tilray Brands. Galectin Therapeutics is trading at a lower price-to-earnings ratio than Tilray Brands, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tilray Brands	$821.31M	0.73	-$2.19B	-$13.65	N/A
Galectin Therapeutics	N/A	N/A	-$30.84M	-$0.41	N/A

In the previous week, Tilray Brands had 10 more articles in the media than Galectin Therapeutics. MarketBeat recorded 13 mentions for Tilray Brands and 3 mentions for Galectin Therapeutics. Tilray Brands' average media sentiment score of 0.29 beat Galectin Therapeutics' score of 0.27 indicating that Tilray Brands is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tilray Brands	3 Very Positive mention(s)	0 Positive mention(s)	7 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
Galectin Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Galectin Therapeutics has a net margin of 0.00% compared to Tilray Brands' net margin of -156.51%. Galectin Therapeutics' return on equity of 0.00% beat Tilray Brands' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tilray Brands	-156.51%	-3.31%	-2.42%
Galectin Therapeutics	N/A	N/A	-164.69%

Tilray Brands presently has a consensus target price of $11.50, indicating a potential upside of 125.05%. Galectin Therapeutics has a consensus target price of $11.00, indicating a potential upside of 368.09%. Given Galectin Therapeutics' higher possible upside, analysts plainly believe Galectin Therapeutics is more favorable than Tilray Brands.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tilray Brands	1 Sell rating(s)	4 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.25
Galectin Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Tilray Brands has a beta of 1.88, indicating that its share price is 88% more volatile than the broader market. Comparatively, Galectin Therapeutics has a beta of 0.47, indicating that its share price is 53% less volatile than the broader market.

Summary

Tilray Brands beats Galectin Therapeutics on 8 of the 15 factors compared between the two stocks.

Get Galectin Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GALT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GALT vs. The Competition

Export

Metric	Galectin Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$159.37M	$2.93B	$6.47B	$12.54B
Dividend Yield	N/A	1.68%	2.69%	5.22%
P/E Ratio	-5.73	17.69	22.39	24.18
Price / Sales	N/A	302.27	520.79	112.26
Price / Cash	N/A	55.72	41.34	57.13
Price / Book	-1.18	3.85	9.84	6.72
Net Income	-$30.84M	$75.85M	$3.57B	$337.19M
7 Day Performance	-12.96%	-1.67%	-1.16%	0.48%
1 Month Performance	3.52%	22.18%	3.85%	5.07%
1 Year Performance	82.17%	21.83%	27.40%	34.25%

Galectin Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GALT Galectin Therapeutics	2.1844 of 5 stars	$2.35 -2.9%	$11.00 +368.1%	+87.6%	$159.37M	N/A	N/A	9	Negative News Gap Up
SLDB Solid Biosciences	2.7909 of 5 stars	$6.72 +1.5%	$16.36 +143.5%	+85.9%	$661.58M	N/A	N/A	100	Analyst Forecast Gap Up
CLYM Climb Bio	3.3178 of 5 stars	$11.45 +4.9%	$20.30 +77.3%	+849.2%	$655.63M	N/A	N/A	9	Positive News
AVTE Aerovate Therapeutics	N/A	$22.21 -5.3%	N/A	+156.4%	$643.76M	N/A	N/A	20	High Trading Volume
CTMX CytomX Therapeutics	2.4146 of 5 stars	$3.77 +0.3%	$12.10 +221.0%	+25.9%	$641.62M	$76.20M	N/A	170

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GALT) was last updated on 6/3/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Galectin Therapeutics (GALT) Competitors

GALT vs. SLDB, CLYM, AVTE, CTMX, and TLRY

How does Galectin Therapeutics compare to Solid Biosciences?

Summary

How does Galectin Therapeutics compare to Climb Bio?

Summary

How does Galectin Therapeutics compare to Aerovate Therapeutics?

Summary

How does Galectin Therapeutics compare to CytomX Therapeutics?

Summary

How does Galectin Therapeutics compare to Tilray Brands?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GALT vs. The Competition

Galectin Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Galectin Therapeutics (GALT) Competitors

GALT vs. SLDB, CLYM, AVTE, CTMX, and TLRY

How does Galectin Therapeutics compare to Solid Biosciences?

Do analysts recommend SLDB or GALT?

Is SLDB or GALT more profitable?

Does the media favor SLDB or GALT?

Which has stronger valuation & earnings, SLDB or GALT?

Do institutionals and insiders have more ownership in SLDB or GALT?

Which has more risk and volatility, SLDB or GALT?

Summary

How does Galectin Therapeutics compare to Climb Bio?

Which has preferable valuation & earnings, GALT or CLYM?

Which has more risk and volatility, GALT or CLYM?

Do insiders and institutionals have more ownership in GALT or CLYM?

Does the media refer more to GALT or CLYM?

Do analysts recommend GALT or CLYM?

Is GALT or CLYM more profitable?

Summary

How does Galectin Therapeutics compare to Aerovate Therapeutics?

Does the media refer more to GALT or AVTE?

Is GALT or AVTE more profitable?

Which has better valuation and earnings, GALT or AVTE?

Do analysts recommend GALT or AVTE?

Do institutionals and insiders have more ownership in GALT or AVTE?

Which has more volatility & risk, GALT or AVTE?

Summary

How does Galectin Therapeutics compare to CytomX Therapeutics?

Does the media favor GALT or CTMX?

Is GALT or CTMX more profitable?

Do analysts prefer GALT or CTMX?

Which has more risk & volatility, GALT or CTMX?

Do institutionals and insiders have more ownership in GALT or CTMX?

Which has higher valuation & earnings, GALT or CTMX?

Summary

How does Galectin Therapeutics compare to Tilray Brands?

Do insiders and institutionals believe in TLRY or GALT?

Which has higher valuation & earnings, TLRY or GALT?

Does the media prefer TLRY or GALT?

Is TLRY or GALT more profitable?

Do analysts recommend TLRY or GALT?

Which has more risk and volatility, TLRY or GALT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GALT vs. The Competition

Galectin Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools